Our focus
Today’s commercial models cannot support pharma’s future. As pharma rethinks its commercial model, it’s time to move from data collection to data connection. Here we reimagine how we work and the value pharma can bring to its customers.
ZS experts and industry leaders share perspectives on how biopharma can transform to advance customers through a context-driven customer strategy.
![848186-Namita-Powers-insight](/https/www.zs.com/content/dam/images/zs-people/848186-Namita-Powers-feature.jpg)
Video
Namita Powers shares ZS’s future commercial model with Reuters Events Pharma
ZS principal Namita Powers talked with Kana Hutton, senior project director, pharma, global, at Reuters, about our vision for the commercial model during Pharma USA 2024. This conversation became an episode of “Pharma Pulse,” a podcast by Reuters Events Pharma. Watch to find out the three moves that companies can make towards creating behavior-changing, personalized customer engagement at scale, as well as the true meaning of “unbundling the rep” and the role of AI in a new model.
![CMOF-POV](/https/www.zs.com/content/dam/images/stock/CMOF-POV-insight.jpg)
Webinar
The rise of the individual: The end of segmentation, the beginning of true personalization
It’s time to start moving away from the segmentation mindset and toward a future of truly personalized customer engagements. Get ready to transform your organization to be more effective in creating individualized connections. See the tangible path toward a model that listens, learns and adapts with purpose for a competitive advantage.
PODCAST
From data collection to data connection: Reinventing pharma’s commercial model
How can pharma use AI and other technology to deliver a better customer experience? Maria Whitman and a panel of ZS experts discuss pharma’s next-generation commercial model.
![Unbundle-the-rep-carousel](/https/www.zs.com/content/dam/images/stock/Unbundle-the-rep-carousel.jpg)
WEBINAR
‘Unbundling’ the rep in the era of personalization
What if pharma companies could create such personalized customer experiences that they could predict an individual’s next need? To make this future a reality, pharma must adopt a new commercial model that evolves the role of the sales rep. Join ZS experts to learn what the new role could look like.
![Susa-Monacelli-Episode-TBP-Podcast-insight](/https/www.zs.com/content/dam/images/stock/FoCM-Reimagine-carousel.png)
Webinar
Pharma’s next evolution: Marketing and the machine
![t-b-p-episode with mike tushman carousel](/https/www.zs.com/content/dam/images/stock/t-b-p-episode-with-mike-tushman-carousel.jpg)
PODCAST
Beyond process improvement: Why organizational architecture matters with Mike Tushman
Maria Whitman interviews Mike Tushman, professor at Harvard Business School, about the importance of organizational architecture during times of transformation. He describes how companies that successfully transform create an organizational architecture that allows both “exploitation” of existing successful strategies and “exploration” of what they might build for the future. He also discusses the role of leaders in driving transformation and the potential of generative AI.
- B
- E
- A
- C
- G
- F
ZS is your partner on a journey to transform pharma’s commercial model
ZS can help you shift the ownership of the customer beyond sales; strategize engagements that earn the right to customers’ attention and achieve true personalization at scale. Learn more about how pharma can rethink its commercial model.
Insights
Meet our pharma commercial model experts
We’ll help you start finding benefits today while driving the organizational change needed to achieve your vision for a more powerful commercial model. Set up your business now for future success.